Allspring Global Investments Holdings LLC Decreases Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Allspring Global Investments Holdings LLC lowered its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 36.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,611 shares of the biopharmaceutical company’s stock after selling 4,898 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Agios Pharmaceuticals were worth $192,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new stake in shares of Agios Pharmaceuticals in the 3rd quarter valued at about $607,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Agios Pharmaceuticals by 25.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,502 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 2,148 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Agios Pharmaceuticals by 1.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,497 shares of the biopharmaceutical company’s stock valued at $928,000 after acquiring an additional 689 shares in the last quarter. Inspire Investing LLC grew its holdings in Agios Pharmaceuticals by 12.0% in the third quarter. Inspire Investing LLC now owns 12,344 shares of the biopharmaceutical company’s stock worth $306,000 after purchasing an additional 1,327 shares during the last quarter. Finally, TD Asset Management Inc grew its holdings in Agios Pharmaceuticals by 90.1% in the third quarter. TD Asset Management Inc now owns 92,218 shares of the biopharmaceutical company’s stock worth $2,282,000 after purchasing an additional 43,719 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. JPMorgan Chase & Co. decreased their price objective on Agios Pharmaceuticals from $31.00 to $30.00 and set a “neutral” rating for the company in a report on Friday, February 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, April 9th. Finally, Royal Bank of Canada dropped their price target on Agios Pharmaceuticals from $43.00 to $42.00 and set an “outperform” rating on the stock in a research note on Friday, February 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $33.50.

Agios Pharmaceuticals Trading Down 0.6 %

NASDAQ:AGIO opened at $31.49 on Friday. The firm has a fifty day simple moving average of $30.11 and a 200-day simple moving average of $25.28. Agios Pharmaceuticals, Inc. has a 12 month low of $19.80 and a 12 month high of $35.50. The company has a market capitalization of $1.77 billion, a P/E ratio of -4.97 and a beta of 0.83.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.72) EPS for the quarter, missing analysts’ consensus estimates of ($1.64) by ($0.08). The firm had revenue of $7.10 million for the quarter, compared to analyst estimates of $7.80 million. Agios Pharmaceuticals had a negative return on equity of 38.08% and a negative net margin of 1,312.64%. The business’s revenue was up 65.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.67 EPS. Equities analysts forecast that Agios Pharmaceuticals, Inc. will post -5.29 EPS for the current year.

Insider Buying and Selling

In related news, Director Jacqualyn A. Fouse sold 7,791 shares of the stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $27.55, for a total value of $214,642.05. Following the transaction, the director now owns 137,396 shares in the company, valued at approximately $3,785,259.80. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, insider James William Burns sold 2,642 shares of the firm’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $86,049.94. Following the completion of the transaction, the insider now owns 34,518 shares of the company’s stock, valued at $1,124,251.26. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jacqualyn A. Fouse sold 7,791 shares of the company’s stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $27.55, for a total transaction of $214,642.05. Following the completion of the sale, the director now directly owns 137,396 shares in the company, valued at $3,785,259.80. The disclosure for this sale can be found here. Insiders sold 16,035 shares of company stock valued at $475,277 over the last quarter. 4.24% of the stock is currently owned by company insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.